Modality
Gene Editing
MOA
MDM2i
Target
KRASG12D
Pathway
Complement
CLL
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
Mar 2022
→ Dec 2031
Phase 1Current
NCT06468609
317 pts·CLL
2022-03→2031-12·Not yet recruiting
317 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-205.7y awayInterim· CLL
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2031-12-20 · 5.7y away
CLL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06468609 | Phase 1 | CLL | Not yet recr... | 317 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |